1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.

DAWN
Day One Biopharmaceuticals, Inc.US flagNASDAQ Global Select
21.53
USD
- -
- -
2.22BMarket Cap
Day One Biopharmaceuticals, Inc.
DAWN
(NASDAQ Global Select)

Recent

price

21.53

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
1.41
- -
1.53
Revenue per Share
-0.3
-0.96
-1.91
-2.17
-2.37
-1.02
- -
-1.04
Basic EPS, GAAP
-0.11
-0.32
-1.53
-1.68
-1.88
-1.63
- -
-1.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.26
-1.3
-3.45
-4.12
-5.75
-5.94
- -
-6.42
Book Value per Share
-0.25
-1.15
7.61
5.07
4.34
5.22
- -
4.11
Tangible Book Value per Share
42
42
37
65
80
93
- -
103
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
131
158
158
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-165.65
-80.76
-80.76
Operating Margin (%)
- -
- -
- -
1
- -
2
4
4
Depreciation Expense
-13
-41
-71
-142
-189
-95
-107
-107
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-72.81
-67.85
-67.85
Profit Margin (%)
25
43
281
331
346
489
425
425
Working Capital
- -
- -
- -
- -
- -
3
3
3
LT Debt
-5
-49
281
332
347
503
441
441
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
3
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
102
103
103
Market Capitalization
655
727
960

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
494
490
485
Cash, Cash Equivalents & STI
453
452
441
Accounts Receivable, Net
20
17
27
Inventories
7
7
6
Total Current Liabilities
51
56
61
Payables & Accruals
47
51
58
ST Debt
- -
- -
- -
Deferred Revenue
2
2
2

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-124.87%
-12.25%
Free Cash Flow
- -
83.88%
-29.4%
Net Income, GAAP
- -
34.29%
12.38%
Sales/Revenue/Turnover
- -
- -
20.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
8
94
29
131
2025
31
34
40
54
158

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.59
-0.61
-0.54
- -
-2.37
2024
-0.72
-0.05
0.38
- -
-1.02
2025
-0.35
-0.29
-0.19
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Silexion Therapeutics Ltd. (SLXNW)
Lyka Labs Limited (LYKALABS.BO)
Orphazyme A/S (ORPHA.CO)
Kringle Pharma, Inc. (4884.T)
Claritas Pharmaceuticals, Inc. (CLAZF)
Syndax Pharmaceuticals, Inc. (SNDX)
Business
I did not find any relevant information about the latest major company changes specifically for Day One Biopharmaceuticals, Inc. in the initial search. I will now conduct targeted searches for recent news, partnerships, acquisitions, product launches, or strategic developments related to Day One Biopharmaceuticals, Inc.

Company News

APIChat

  • prnewswire.com

    Servier completes the acquisition of Day One Biopharmaceuticals

  • prnewswire.com

    Servier completes the acquisition of Day One Biopharmaceuticals

  • prnewswire.com

    Servier finalise l'acquisition de Day One Biopharmaceuticals

  • prnewswire.com

    Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?

  • defenseworld.net

    Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year High – What’s Next?

  • businesswire.com

    Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN

  • 247wallst.com

    Here Are Wednesday’s Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More

  • defenseworld.net

    Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen

  • 247wallst.com

    Here Are Tuesday’s Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe’s, Qualcomm, Rivian, Strategy and More

  • prnewswire.com

    Are DAWN and TALK Obtaining Fair Deals for their Shareholders?

  • zacks.com

    DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier

  • businesswire.com

    Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN

  • fool.com

    Stock Market Today, March 6: Energy Stocks Rise as Oil Closes Over $90 on Middle East Tensions

  • newsfilecorp.com

    SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN)

  • prnewswire.com

    Shareholder Alert: The Ademi Firm investigates whether Day One Biopharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders

  • prnewswire.com

    $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)

  • businesswire.com

    DAWN Stock Alert: Halper Sadeh LLC is Investigating Whether Day One Biopharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

  • benzinga.com

    Day One Shares Surge After $2.5B Servier Deal

  • reuters.com

    Servier to buy Day One Biopharmaceuticals for total equity value of $2.5 billion

  • globenewswire.com

    Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio